Drag across the chart to measure the move between two points.Delayed 15 minutes · monthly closing basis
Business overview
The DAIICHI SANKYO Group’s principal business is the manufacture and sale of pharmaceuticals and related products. It operates through 7 companies in Japan and 38 overseas companies. Under its 2035 Vision, “Trusted healthcare innovator transforming the lives of people through our science and technology,” the Group is pursuing its Sixth Mid-Term Management Plan (FY2026–FY2030), centered on transforming and growing its oncology business. Its FY2030 targets are net sales of at least ¥3 trillion, operating profit of at least ¥600 billion, EPS of at least ¥260, and DOE of at least 10.0%. Initiatives include increasing oncology revenue to at least ¥2.3 trillion by FY2030. The Group is advancing Operational Excellence, rebuilding its global supply chain, improving productivity through AI, implementing a unified ERP platform, and managing its domestic and overseas sites on an integrated basis. It intends to maintain and expand progressive dividends as part of its shareholder return policy.
Recurring subjects
No threads yetThis company's filings have not been read yet. We are adding them progressively.